<DOC>
	<DOCNO>NCT02639910</DOCNO>
	<brief_summary>This single arm , multicenter , open-label study MOR00208 combine idelalisib adult patient R/R CLL R/R SLL pretreated BTK inhibitor ( e.g. , ibrutinib ) single agent part combination therapy .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety MOR208 With Idelalisib R/R CLL/SLL Patients Pretreated With BTKi ( COSMOS )</brief_title>
	<detailed_description>The purpose study evaluate clinical safety efficacy MOR00208 combine idelalisib . The study include safety run-in phase evaluation safety data . This evaluation do Independent Data Monitoring Committee .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Major inclusion criterion Diagnosis/Trial Population Chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) : history diagnosis CLL SLL meet IWCLL diagnostic criterion histologically confirm diagnosis SLL lymph node biopsy indication treatment define IWCLL guideline Patients must follow : relapsed refractory disease receive BTKi therapy intolerance therapy singleagent combination therapy BTKi least one month must patient 's recent prior anticancer therapy ECOG performance status 0 2 Patients past medical history autologous allogeneic stem cell transplantation must exhibit full hematological recovery Laboratory Values Patients must meet adequate bone marrow function adequate hepatic renal function Other Inclusion Criteria â€¢ Females childbearing potential must use highly effective method contraception Major exclusion criterion Diagnosis Patients : nonHodgkin 's lymphomas CLL/SLL transform CLL/SLL Richter 's syndrome active uncontrolled autoimmune cytopenia Previous Current Treatment Patients , within 14 day prior D1 dosing : discontinue CD20targeted therapy , chemotherapy , radiotherapy , investigational anticancer therapy lymphoma specific therapy systemic corticosteroid dos great prednisone equivalent 20 mg/day receive live vaccine exception vaccination influenza inactivate virus pneumococcal disease Patients : recover sufficiently adverse toxic effect prior therapy previously treat CD19targeted therapy PI3K inhibitor history previous severe allergic reaction prior monoclonal antibody therapy , and/or excipients contain study drug formulation Patients ongoing inflammatory bowel disease ulcerative colitis , Crohn 's disease , chronic diarrhoea , severe chronic obstructive pulmonary disease , pulmonary emphysema druginduced pneumonitis diagnose previous medical history .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CD19</keyword>
	<keyword>MOR208</keyword>
	<keyword>MOR00208</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>COSMOS</keyword>
</DOC>